

Index

A

- AAFP. *See* American Academy of Family Physicians
- AAP. *See* American Academy of Pediatrics
- AAP/AAFP guidelines, for AOM diagnosis, 26–27
- Abscess, in pharyngitis, 19
- Acetaminophen, 27
- Acid-fast bacillus (AFB), testing, 51
- ACIP. *See* Advisory Committee of Immunization Practices; American College of Immunization Practices
- ACOG. *See* American College of Obstetrics and Gynecology
- Acquired immune deficiency syndrome (AIDS), 167, 170
- Actinobacillus actinomycetemcomitans*, 244
- Acute bacterial sinusitis, 59
- Acute bronchitis, 40–42
- Acute diarrhea, 67, 79–81
- Acute epididymitis, 150–152
- Acute exacerbation of COPD, diagnosis of, 34
- Acute gastroenteritis, 82
- Acute gouty arthritis, 194–195
- Acute hepatitis A infection, diagnosis of, 86–88
- Acute osteomyelitis, 214–215
- Acute otitis media
- bacterial pathogens and vaccinations for, 26
 - diagnosis of, 26–27
 - epidemiology and risk factors, 25
 - treatment of, 27–30
- Acute proctitis, 160–161
- Acute respiratory distress syndrome, 271
- Acute retroviral syndrome, 168
- Acute sinusitis
- clinical presentation and epidemiology of, 58
 - diagnosis of, 59–61
 - nasal steroids, 62
 - pathophysiology, 57–58
 - treatment of, 61–62
- Acute viral hepatitis, differential diagnosis of, 87–88
- Acyclovir, 108–110
- ADA. *See* American Diabetes Association
- Adefovir, 92
- Adenoidectomy, 30
- Adenovirus, 87
- Adolescents, STD risk and, 106
- Adult immunization schedule, recommendation for, 276
- Adult vaccination
- Diphtheria Tetanus acellular Pertussis, 283–285
 - hepatitis A virus, 277–278
 - hepatitis B virus, 275–277
 - human papillomaviruses, 280–281
 - influenza, 282–283
 - measles, mumps, and rubella, 278–279
 - meningococcal disease, 285–286
 - pneumococcal disease, 281–282
 - varicella, 279–280
 - Zoster, 280
- Advisory Committee of Immunization Practices, 88, 275
- Alanine aminotransferase, 86–87
- Albuterol metered-dose inhalers, 42
- ALT. *See* Alanine aminotransferase
- Amantadine, 6
- American Academy of Family Physicians, 25
- American Academy of Pediatrics, 18, 25
- American College of Immunization Practices, 199–200
- American College of Obstetrics and Gynecology, 279
- American Diabetes Association, 206

- American Heart Association (AHA), 243, 250–251
- American Thoracic Society, 3
- Amoxicillin, 9, 28, 61, 130, 134, 269. *See also* Antibacterial agents, in CAP
- Amoxicillin-Clavulanate, 10, 199, 269
- Amoxicillin-clavulanic acid, 20, 28, 237
- Ampicillin/sulbactam, 148
- Ankle brachial index (ABI) screening, 206
- Antibacterial agents, in CAP, 9–11
- Antibiotic therapy
 - in acute bacterial sinusitis, 62
 - for acute osteomyelitis, 219
 - for AOM, 28–29
 - for COPD treatment, 37–39
 - for diabetic foot infections, 208–210
 - for infective endocarditis, 249–251
 - for skin infection, 199–201
 - for urinary tract infections, 268–270
- Anti-HAV IgM, 86
- Antiretroviral therapy, 171, 173, 180
- Antistreptolysin O (ASO), 18
- Antiviral medication, for HIV, 175–176
- AOM. *See* Acute otitis media
- Arcanobacterium haemolyticum*, 18–19
- ARDS. *See* Acute respiratory distress syndrome
- ART. *See* Antiretroviral therapy
- Arterial blood gas (ABG), analysis of, 35
- ASCUS. *See* Atypical squamous cells of undetermined significance
- Aspartate aminotransferase, 86–87
- AST. *See* Aspartate aminotransferase
- Asymptomatic bacteriuria, 267–270
- Atripla™, 174
- ATS. *See* American Thoracic Society
- Atypical squamous cells of undetermined significance, 179
- Azithromycin, 29, 107–108, 111, 113, 116, 125–127, 129–130, 134
- B**
- Bacille Calmette-Guérin vaccine, 45
- Bacillus anthracis*, 12
- Bacillus cereus*, 79
- Bacterial diarrhea, mechanisms of, 79
- Bacterial meningitis
 - complications of, 257
 - diagnosis of, 255
 - HIB vaccine, 258
- Bacterial pathogens
 - and COPD, 37
 - and pharyngitis, 18–19
- Bacterial vaginosis (BV), 127
 - diagnosis of, 137
 - HIV infection and, 140
 - pregnancy and, 139–140
 - treatment of, 137–139
- Bacteroides* spp., 198, 200
- BCA. *See* Bichloroacetic acid
- BCG. *See* Bacille Calmette-Guérin vaccine
- Benign prostatic hypertrophy, 261
- Benzathine penicillin G, 115–118, 120, 122–23
- Benzoic acid, 155
- Bichloroacetic acid, 154
- Bioethical issues
 - and law, 290
 - principles of, 289–290
- Bioterrorism and pneumonia, 12
- Bloody diarrhea
 - causes of, 80
 - diagnosis of, 82
- Bordetella pertussis*, 41, 283
- Borrelia burgdorferi*, 190, 235
- BPH. *See* Benign prostatic hypertrophy
- Bronchodilator therapy, 36
- Butoconazole, 143
- C**
- CABG. *See* Coronary artery bypass graft
- Callus formation, in diabetic foot infections, 203
- Campylobacter*, 80, 83–84
- CA-MRSA. *See* Community-acquired MRSA strains
- Candida albicans*, 136, 140, 142
- Candida glabrata*, 144
- Candidiasis. *See* Vulvovaginal candidiasis
- CAP. *See* Community-acquired pneumonia
- Capnocytophaga canimorsus*, 198
- Carcinoma erysipelatoides, 195
- Cardiobacterium hominis*, 244
- CDC. *See* Centers for Disease Control and Prevention
- Cefazolin, 196
- Cefixime, 133, 136
- Cefotaxime, 135
- Cefotetan, 147
- Cefoxitin, 149
- Cefpodoxime, 136
- Cefpodoxime proxetil, 269
- Ceftizoxime, 135
- Ceftriaxone, 107–108, 116–117, 120, 132–133, 135–136, 149, 151, 161, 232, 237, 257

- Cefuroxime, 237
- Celiac disease, 82
- Cellulitis
 clinical presentation and diagnosis
 of, 192
 pathophysiology, 189–190
- Centers for Disease Control and Prevention,
 15, 59, 85, 105, 237, 275
- Centor Clinical Prediction Rules, usages
 of, 17
- Cephalexin, 196, 233
- Cephalosporins, 10, 28–29, 133–134, 149,
 196, 256, 272. *See also*
 Antibacterial agents, in CAP
- Cerebrospinal fluid, 14, 115, 117, 119,
 121, 238
- Cervical cancer screening
 hepatitis A, 156–158
 hepatitis B, 158–160
 hepatitis C, 160
- Cervical intraepithelial neoplasia, 281
- Cervicitis, 126–127
- Chancroid, 107
- CHD. *See* Congenital heart disease
- Chest radiograph, 50–51
- Chest x-ray (CXR), 169
- CHF. *See* Congestive heart failure
- Chlamydial genital infections, 128–130
- Chlamydia pneumoniae*, 18–19, 37
- Chlamydia trachomatis*, 106, 112, 124–129,
 131, 134–135, 146, 151–152, 232,
 262, 265
- Chlamydia pneumoniae*, 3, 6
- Chloramphenicol, 12
- Chronic diarrhea, 67, 81
- Chronic obstructive pulmonary disease, 6
 causes and pathogenesis of, 33–34
 diagnosis of, 34–35
 discharge of patients, 40
 therapies for, 36–40
- Chronic osteomyelitis, 215
- Cierny–Mader system, for osteomyelitis, 213
- Cigarette smoking and COPD, 33–34
- CIN. *See* Cervical intraepithelial neoplasia
- Ciprofloxacin, 12, 108, 111, 201, 257, 270
- Clarithromycin, 29, 196
- Clindamycin, 10, 20, 29, 138–139, 148,
 196, 233. *See also* Antibacterial
 agents, in CAP
- Clinical ethics, analysis of
 case studies for, 292–299
 definition of, 289
 professional statements and oaths in, 290
 steps for analyzing, 291
- Clostridium botulinum*, 79
- Clostridium difficile*, 11, 80, 83
 diarrhea caused by, 82
 laboratory tests of, 81
- Clostridium tetani*, 284
- Clotrimazole, 143–144
- Codeine, 42
- Community-acquired MRSA strains,
 190, 196
- Community-acquired pneumonia
 chest radiography and pathogens in, 4
 diagnostic testing methods for, 4–6
 discharge of patient, 11
 epidemiology of, 3
 performance assessment of, 13
 specific antibacterial agents, 9–11
 treatment of, 7–9
- Complete blood cell count (CBC), 60, 169
- Complicated UTIs, treatment of, 271
- Congenital heart disease, 244, 250
- Congenital rubella syndrome, 278
- Congestive heart failure, 7, 246, 248–249
- Contact dermatitis, 194. *See also* Skin
 and soft tissue infections
- Continuous positive airway pressure, 38
- COPD. *See* Chronic obstructive pulmonary
 disease
- Coronary artery bypass graft, 249
- Corticosteroid therapy, 36–37
- Corynebacterium diphtheriae*, 18–19
- Costovertebral angle, 263
- Coumadin therapy, 248
- Coxsackie B virus, 87
- CPAP. *See* Continuous positive airway
 pressure
- C-reactive protein level, 208, 221
- CRP. *See* C-reactive protein level
- CRS. *See* Congenital rubella syndrome
- Cryptosporidium*, 80
- CSF. *See* Cerebrospinal fluid
- CURB-65, usages of, 7
- CVA. *See* Costovertebral angle
- Cytomegalovirus (CMV), 87, 146, 169
- Cytotoxin, role in bacterial diarrhea, 79
- D**
- Deep venous thrombosis, 194
- DEET. *See* *N,N*-diethyl-3-methylbenzamide
- Dexamethasone, 256
- Dextromethorphan, 42
- DFA. *See* Direct fluorescent antibody
- DGI. *See* Disseminated gonococcal
 infection

Diabetic foot infections
 causes of, 203–204
 clinical manifestation, 204–205
 laboratory diagnostics for, 206–208
 therapies for, 208–210
 treatment effects for, 211
 wound assessment and examination,
 205–206

Diabetic neuropathy, 204

Diarrhea
 bacterial pathogens for, 79
 clinical presentation, 79–82
 complications associated with, 83–84
 definition of, 67
 treatment for, 82–83

Dicloxacillin, 196, 233

Didanosine, 174, 177

N,N-diethyl-3-methylbenzamid 236

Digital rectal examination, 263–264

Diphtheria Tetanus acellular Pertussis (DTaP),
 vaccination for, 283–285

Direct fluorescent antibody, 114

Disseminated gonococcal infection, 135

Dog and cat bites, skin infections with
 antibiotics in preventing, 199
 bacterial infection associated with, 198
 immunization for, 199–200
 wound management, 198–199

Doxycycline, 9–10, 61, 111, 113, 115, 117,
 125, 127, 129, 147–149, 151, 161,
 196, 199. *See also* Antibacterial
 agents, in CAP

DRE. *See* Digital rectal examination

Dry and wet gangrene, 208

E

Early Lyme Disease, treatment of,
 237–238

EBV. *See* Epstein-Barr Virus

Ectoparasitic infections
 pediculosis pubis, 161–162
 scabies, 162–163

Efavirenz, 174

Eikenella corrodens, 200, 244

Emtricitabine, 174

Engerix-B, 92

Entamoeba histolytica, 79–80

Entecavir, 92

Enteritis, 160–161

Enterotoxin, role in bacterial diarrhea, 79

Enzyme immunoassay (EIA), 94

Enzyme-linked immunosorbent assay
 (ELISA) test, 18, 48, 172, 236

Epididymitis, 150
 diagnosis of, 151
 management of sex partners, 152
 treatment of, 151

Epstein-Barr Virus, 18–19, 87

EPT. *See* Expedited partner therapy

Erysipelas
 clinical presentation and diagnosis of, 192
 pathophysiology, 189–190

Erythrocyte sedimentation rate, 60, 208, 221

Erythromycin, 108, 112–113, 125,
 129–130, 196

Escherichia coli, 37, 79, 83, 213, 253, 259

ESR. *See* Erythrocyte sedimentation rate

Expedited partner therapy, 105

F

Famciclovir, 109–110

FEV₁. *See* Forced expiratory volume
 in 1 second

Fixed drug reaction, 194. *See also* Skin
 and soft tissue infections

Flaviviridae, 94

Fluconazole, 143–144

Fluorescent treponemal antibody
 absorbed, 114

Fluoroquinolones, 10, 12, 134, 136, 199.
See also Antibacterial
 agents, in CAP

Forced expiratory volume in 1 second, 35

Forced vital capacity, 36

Fosfomycin, 269

Franciella tularensis, 12

FTA-ABS. *See* Fluorescent treponemal
 antibody absorbed

Fusobacterium spp., 198, 200

FVC. *See* Forced vital capacity

G

GABHS. *See* Group A β -hemolytic
 streptococci

Gardnerella vaginalis, 136,
 140, 146

Gastroenteritis
 clinical presentation of, 79–82
 complications of, 83–84
 pathophysiology of, 67
 bacterial causes of, 68–74
 parasitic causes of, 77–78
 viral causes of, 75–76
 treatment of, 82–83

Gastroesophageal reflux disease, 19

Gastrointestinal infections

- gastroenteritis, 67
 - bacterial causes of, 68–74
 - clinical presentation of, 79–82
 - complications of, 83–84
 - parasitic causes of, 77–78
 - protozoan causes of, 79
 - treatment of, 82–83
 - viral causes of, 75–76

Hepatitis

- HAV, 85–89
- HBV, 89–93
- HCV, 93–97
- HDV, 97–99
- HEV, 100–101

GBS. *See* Group B *Streptococcus*;
Guillain-Barré syndrome

Genital herpes and pregnancy, 110–111

Genital HSV infection
diagnosis of, 108
treatment of, 108–110

Genital ulcers, 107–108

Genital warts, 153–156

Gentamicin, 12, 112, 148

GERD. *See* Gastroesophageal
reflux disease

Giardia, 79–80, 83

Giardia vaginalis, 137

GISP. *See* Gonococcal Isolate Surveillance
Project

Glucose-6-phosphate-dehydrogenase, 270

GNID. *See* Gram-negative intracellular
diplococci

GOLD guidelines, for COPD, 36

Gonococcal conjunctivitis, treatment of,
135–136

Gonococcal infections
in cervix, urethra and rectum, 132–133
diagnosis of, 131
in pharynx, 133–134
treatment of, 131–132

Gonococcal Isolate Surveillance
Project, 132

Gonococcal meningitis and endocarditis, 136

G6PD. *See* Glucose-6-phosphate-
dehydrogenase

Gram-negative intracellular diplococci, 124

Granuloma inguinale, treatment of, 111–112

Group A β -hemolytic streptococci, 15
complications associated with, 20–21
in septic joints, 230
treatments of, 19–20

Group B *Streptococcus*, 266

Guillain-Barré syndrome, 278

H

HAART. *See* Highly active ART

Haemophilus ducreyi, 107

Haemophilus influenzae, 4, 26, 37, 61, 146,
200, 231

Haemophilus influenzae type B, 26, 253

Haemophilus spp., 244

HAIG. *See* Hepatitis A immunoglobulin

HAP. *See* Hospital-acquired pneumonia

Havrix, 88

HBIG. *See* HBV Ig; Hepatitis B
immunoglobulin

HBV and HDV, infection of, 98–99

HBV Ig, 158

HBV infection, serologic test of, 159

HCAP. *See* Healthcare-associated
pneumonia

HCC. *See* Hepatocellular carcinoma

Healthcare-associated pneumonia, 9

HELLP. *See* Hemolysis Elevated Liver
enzymes and Low Platelets

Hemolysis Elevated Liver enzymes and Low
Platelets, 180

Hemolytic-uremic syndrome, 83–84

Hepadnaviridae, 89

Hepatitis A immunoglobulin, 89

Hepatitis A virus (HAV), 156

clinical manifestation of, 86

complications of, 88

diagnosis and characteristics of,
87–88

laboratory test of, 86–87

pathophysiology of, 85

postexposure prophylaxis of, 158

prevention and screening of, 88–89

prevention and vaccination of, 157

treatment of, 88

vaccination for, 89, 277–278

Hepatitis B immunoglobulin, 93

Hepatitis B surface (HBs), 90

Hepatitis B virus (HBV), 89–90

clinical manifestation and laboratory
investigation of, 90

diagnosis and treatment of, 158

differential diagnosis of, 90–91

pathophysiology of, 89–90

postexposure prophylaxis of,
159–160

prevention of, 92–93, 158–159

treatment of, 92

vaccination for, 93, 275–277

Hepatitis C virus (HCV), 93–97, 160

clinical manifestation of, 94

differential diagnosis of, 96–97

Hepatitis C virus (HCV) (*cont.*)
 laboratory investigation of, 94–96
 pathophysiology of, 94
 prevention of, 97

Hepatitis D virus (HDV), 97
 clinical manifestation of, 98–99
 pathophysiology of, 98
 prevention of, 99
 treatment of, 99

Hepatitis E virus (HEV)
 clinical manifestation
 and pathophysiology of, 100
 prevention of, 101
 treatment of, 100–101

Hepatocellular carcinoma, 92, 158

Herpes simplex virus (HSV), 18, 87, 110

Herpes zoster vaccine, 280

HIB. *See Haemophilus influenzae* type B

Hibiclens, 197

HIB meningitis, 258

HIB vaccine, 253, 258

Highly active ART, 177, 179

Hospital-acquired pneumonia, 9

HPV infection, 152

HSV-2 infection, 109

Human bites, skin infection with, 200–201

Human immunodeficiency virus (HIV), 167
 bacterial vaginosis and, 140
 in children, 181
 chlamydial genital infection in, 130
 clinical manifestation of, 168
 development of resistance, 177–179
 differential diagnosis of, 172
 gonococcal infection in, 134
 infection
 detection of, 106–107
 starting therapy, 174
 latent syphilis in, 121–122
 OIs and treatment of, 168–172
 pathophysiology of, 168
 postexposure prophylaxis, 181–184
 pregnancy in, 179–180
 primary and secondary syphilis,
 120–121
 syphilis in, 120
 testing and laboratory studies of, 172
 treatment of, 173–177
 VVC in, 145

Human papillomaviruses (HPV), vaccination
 for, 280–281

HUS. *See Hemolytic–uremic syndrome*

Hyperbaric oxygen therapy, for
 osteomyelitis, 220

Hypoxic patient, treatment, 36

I

IBS. *See Irritable bowel syndrome*

IDSA. *See Infectious Diseases Society of America*

IDSA/ATS recommendation for CAP
 treatment, 7

IgM antibody, 86

Imiquimod, 153

Infectious bursitis, 228
 bacterial pathogens for, 231
 diagnosis of, 230
 treatment for, 233

Infectious Diseases Society of America, 3, 15,
 55, 254, 256

Infective endocarditis (IE)
 antibiotic prophylaxis, 249–251
 clinical manifestation of, 245–247
 complications of, 248–249
 pathophysiology of, 243–245
 treatment of, 247–248

Influenza
 prevention of, 6, 13
 vaccination for, 282–283

Inhalational anthrax, 12

In intravenous drug users (IVDUs), 245

Inpatient empiric therapy, of CAP, 7–8

Insect bites, 194. *See also* Skin and soft
 tissue infections

α -Interferon, 9

Interferon α -2a, 92

Intrauterine device, 150

Intravenous acyclovir therapy, 110

Intravenous drug abuse, 167

Invasins production, role in bacterial
 diarrhea, 79

Invasive ventilation, 38, 40

Irritable bowel syndrome, 81–82

Isospora, 83

IUD. *See Intrauterine device*

IVDA. *See Intravenous drug abuse*

Ivermectin, 161–163

Ixodes ticks bite and Lyme disease, 236

J

Jarisch-Herxheimer reaction, in STD,
 114, 123

K

Kawasaki disease, 19

Ketolides, 9. *See also* Antibacterial
 agents, in CAP

Kingella kingae, 244

Klebsiella granulomatis, 111

Klebsiella pneumoniae, 37

L

Lactate dehydrogenase (LDH), 169

Lactobacillus sp., 137

LAIV. *See* Live-attenuated influenza vaccine

Lamivudine, 92, 174

Latent syphilis

clinical evaluation of, 117

treatment of, 116

Latent tuberculosis infection, 45, 52–55

Legionella sp., 3, 5–6

Levofloxacin, 125, 129, 151, 201

LGV. *See* Lymphogranuloma venereum

Lindane, 162

Listeria monocytogenes, 253

Live-attenuated influenza vaccine, 283

LTBI. *See* Latent tuberculosis infection

Lyme disease, 190

diagnosis of, 236–237

epidemiology of, 235

post-Lyme disease syndromes, 239

preventive measures of, 235–236

treatment of early and late, 237–239

Lymphogranuloma venereum, 112–113

M

MAC/MAI. *See* Mycobacterium avium complex/intracellulare

Macrolides, 9. *See also* Antibacterial agents, in CAP

Magnetic resonance imaging (MRI), 207

Malathion, 161

MCV4 vaccine, 286

MDRO. *See* Multidrug-resistant organisms

Measles, mumps, and rubella (MMR), vaccination for, 278

Megitt–Wagner diabetic foot ulcer classification, 206

Meningitis

bacterial

complications of, 257

diagnosis of, 255

HIB vaccine, 258

clinical manifestation of, 254–255

differential diagnosis of, 255

pathophysiology of, 253–254

treatment of, 256–257

Meningococcal disease, vaccination for, 285–286

Men who have sex with men, 88, 106, 130, 132, 134, 167

Methicillin/oxacillin-resistant *S. aureus*, 245

Methicillin-resistant *S. aureus*, 9, 190, 209, 230

Methicillin-susceptible *S. aureus*, 190

Metronidazole, 83, 126, 138–139, 141–142, 149

Miconazole, 143

Microbiologic diagnosis, for osteomyelitis, 216–217

Microimmunofluorescence assay (MIF), 6

Minocycline, 196

Mitral valve prolapse, 244

Mobiluncus sp., 137

Moraxella catarrhalis, 9, 26, 37

MPSV4 vaccine, 285–286

MRSA. *See* Methicillin-resistant *S. aureus*

MRSA/ORSA. *See* Methicillin/oxacillin-resistant *S. aureus*

MSM. *See* Men who have sex with men

MSSA. *See* Methicillin-susceptible *S. aureus*

Multidrug-resistant organisms, 9

Mupirocin, 197

MVP. *See* Mitral valve prolapse

Mycobacterium avium complex/intracellulare, 169

Mycobacterium tuberculosis, 45

Mycoplasma genitalium, 124, 126–127, 146

Mycoplasma hominis, 137, 146

Mycoplasma pneumoniae, 3, 18–19, 41

N

NAAT. *See* Nucleic acid amplification tests

Nafcillin, 196

Nasal steroids, in acute bacterial sinusitis, 63

Necrotizing fasciitis, 192–193. *See also* Skin and soft tissue infections

Neisseria gonorrhoeae, 18, 106, 124–127, 131, 133, 136, 146, 151–152, 230–231, 262, 265

Neisseria meningitidis, 253, 256

Neoplastic processes, for pharyngitis, 19

Neurosyphilis, 119–120

Nevirapine, 180

NGU. *See* Nongonococcal urethritis

NIPPV. *See* Noninvasive positive pressure ventilation

Nitrofurantoin, 269

NNRTI. *See* Nonnucleotide reverse transcriptase inhibitors

Nonbloody diarrhea

causes of, 80

diagnosis of, 81–82

viral pathogenesis in, 79

- Nongonococcal urethritis, 124
 Noninvasive positive pressure ventilation, 38
 Nonnucleotide reverse transcriptase inhibitors, 175, 178–179
 Non-occupational HIV exposures, treatment, 182
 Nonsteroidal anti-inflammatory drugs (NSAIDs), 272
 NRTI. *See* Nucleotide/side reverse transcriptase inhibitors
 Nucleic acid amplification tests, 124
 Nucleotide/side reverse transcriptase inhibitors, 175, 179
 Nystatin, 143
- O**
- Ofloxacin, 125, 129, 151
 Opportunistic infections (OIs), 168
 Oseltamivir, 6
 Osteomyelitis
 - acute and chronic, 214–215
 - aftercare of patients, 220–221
 - causes of, 213–214
 - clinical features of, 213
 - diagnosis of, 215–216
 - hyperbaric oxygen therapy, 220
 - laboratory diagnostics for, 216–217
 - medical therapy, 219–220
 - prognosis and prevention of, 221–222
 - radiologic tests for, 217
 - surgical therapy, 218–219
 Outpatient empiric therapy, of CAP, 7–8
 Oxacillin, 196
- P**
- PAN. *See* Polyarteritis nodosa
 Panton-Valentine leukocidin (PVL) toxin, 191
 Papillomatosis, 156
 Paranasal sinuses, 57
 Paromomycin, 83
Pasteurella multocida, 198–199
 PCP. *See* *Pneumocystis carinii* pneumonia
 PCV. *See* Pneumococcal conjugate vaccine
 PCV7 vaccine, 26
 Peak expiratory flow, 35
 Pediculosis pubis, 161–162
 PEF. *See* Peak expiratory flow
 Peginterferon α -2a, 92
 Pegylated interferon, 96
 Pelvic inflammatory disease, 127, 134, 145, 263
 - after care of, 149
 - diagnosis of, 146
 - oral therapy of, 148–149
 - parenteral treatment of, 147–148
 - prevention of, 150
 - treatment of, 147
 Penicillins, 20, 119, 196, 237
 - allergy with
 - in latent syphilis and treatment, 117–118
 - in neurosyphilis and treatment, 120
 - in primary and secondary syphilis and treatment, 115–116, 121
 - in tertiary syphilis and treatment, 118
 - role in fetal infection, 122*Peptostreptococci* sp., 198, 200
 Peripheral vascular disease, 203
 Permethrin, 161–162
 Pharyngitis
 - causes and diagnosis for, 18–19
 - clinical manifestation of, 16–17
 - complications in, 20–22
 - epidemiology, 15
 - laboratory diagnostics for, 17–18
 - management of, 22–23
 - pathophysiology of, 16
 - therapy for, 19–20*Picornaviridae*, 85
 PID. *See* Pelvic inflammatory disease
 Piperonyl butoxide, 161
 Pneumatic otoscopy, 27
 Pneumococcal conjugate vaccine, 281
 Pneumococcal disease, vaccination for, 281–282
 Pneumococcal polysaccharide vaccine, 13–14
Pneumocystis carinii pneumonia, 167
 Pneumonia
 - and bioterrorism, 12
 - in elderly persons, 11
 Pneumonia Severity Index, 7
 Podofilox, 153
 Podophyllin, 153, 155
 Polyarteritis nodosa, 92
Porphyromonas spp., 137, 198, 200
 Positive predictive value, 146
 Postbronchodilator spirometry, 34
 Postexposure prophylaxis (PEP), 159, 173
 Post-Lyme Disease syndromes, 239
 Poststreptococcal glomerulonephritis, 21
 PPD. *See* Purified protein derivative
 PPV. *See* Positive predictive value; Purified polysaccharide vaccine

Pregnancy

- bacterial vaginosis and, 139–140
- chlamydial genital infection in, 130
- erythromycin and azithromycin role, 113
- genital herpes and, 110–111
- in HIV-positive patient, 179–180
- latent and tertiary syphilis in, 118
- Neisseria gonorrhoeae* infection
 - and treatment in, 134
- neurosyphilis in, 120
- syphilis in, 122–123
- Pressure support ventilation, 38
- Prevotella* spp., 137, 198, 200
- Primary syphilis, 115–116
- Procaine penicillin, 119
- Proctitis, 160–161
- Proctocolitis, 160–161
- Prostate-specific antigen, 266
- Prosthetic valve endocarditis, 244
- PSA. *See* Prostate-specific antigen
- Pseudomonas aeruginosa*, 37, 213, 231
- PSI. *See* Pneumonia Severity Index
- PSV. *See* Pressure support ventilation
- Purified polysaccharide vaccine, 281
- Purified protein derivative, 46
- PVD. *See* Peripheral vascular disease
- PVE. *See* Prosthetic valve endocarditis
- Pyomyositis, 193. *See also* Skin and soft tissue infections
- Pyrethrins, 161

Q

- QuantiFERON®-TB Gold (QFT-G) test, 48–50
- Quinolone, 83
- Quinolone-resistant *Neisseria gonorrhoeae* (QRNG), 131–132

R

- Rabies prophylaxis, 200
- Rapid antigen detection (RAD) tests, 18
- Rapid detection test, 6
- Rapid plasma reagin, 114, 171
- Recombivax HB, 92
- Recurrent genital herpes, 109–110
- Recurrent VVC, 144
- Respiratory syncytial virus, 6
- Rheumatic fever, 22
- Ribavirin, 96
- Rifampin, 257
- Rifampin and pyrazinamide (RIF-PZA) treatment, 52

Rimantadine, 6

Ritonavir, 177

RPR. *See* Rapid plasma reaginRSV. *See* Respiratory syncytial virusRVVC. *See* Recurrent VVC

S

- Safety net prescriptions, 28
- Salmonella*, 80, 82–83
- Scabies, 162–163
- Scarlet fever, 22
- Secondary syphilis, 115–116
- Semmes-Weinstein 5.07, 206
- Septic arthritis
 - bacterial pathogens for, 230–231
 - diagnosis of, 228–230
 - epidemiology of, 225
 - pathogenesis of, 226–227
 - symptoms of, 227–228
 - treatments for, 231–233
- Serratia marcescens*, 213
- Serum α -fetoprotein (AFP), 92
- Sex partners, management of, 114–115, 127
 - in chlamydial infections, 129–130
 - gonococcal infections, 133–134
- Sexual assault and STD, 163–165
- Sexually transmitted diseases (STD)
 - cervical cancer screening, 156–160
 - cervicitis, 126–128
 - chlamydial genital infections, 128–130
 - diseases characterized by genital ulcers, 107
 - enteritis, 160–161
 - epididymitis, 150–152
 - genital HSV infection, 108–111
 - genital warts, 153–156
 - gonococcal conjunctivitis, 135–136
 - gonococcal infections, 131–134
 - gonococcal meningitis
 - and endocarditis, 136
 - Granuloma inguinale, 111–112
 - HIV, 167
 - care of infant and, 181
 - clinical manifestation of, 168
 - detection, 106–107
 - development of resistance, 177–179
 - differential diagnosis of, 172
 - infected persons, 120–122
 - OIs and treatment of, 168–172
 - pathophysiology of, 168
 - postexposure prophylaxis, 181–184
 - pregnancy in, 179–180

- Sexually transmitted diseases (STD) (*cont.*)
 testing and laboratory studies of, 172–173
 treatment of, 173–177
 HPV infection, 152
 lymphogranuloma venereum, 112–113
 neurosyphilis, 119–120
 partner management, 105
 pediculosis pubis, 161–162
 pelvic inflammatory disease, 145–150
 proctitis, 160–161
 proctocolitis, 160–161
 scabies, 162–163
 special populations, 106
 syphilis, 113–119
 treatment of, 107–108
 urethritis, 124–126
 vaginal discharge, 136
 bacterial vaginosis, 137–140
 trichomoniasis, 140–142
 vulvovaginal candidiasis, 142–145
- Shigella*, 79, 83
- SIL. *See* Squamous intraepithelial lesion
- Sinusitis, definition of, 57
- Skin and soft tissue infections, 189
 diagnosis of, 195
 by dog and cat bites, 198–200
 human bites, 200–201
 invasive infections, 192–193
 noninfectious condition in, 193–195
 pathogens for, 190–191
 therapies for, 195–197
- SNAPs. *See* Safety net prescriptions
- Sore throat. *See* Pharyngitis
- Spectinomycin, 133–135
- Sphenoid sinuses, 57
- Spirometry, 34
- Sputum cultures, for TB diagnosis, 51–52
- Squamous intraepithelial lesion, 152
- SSTI. *See* Skin and soft tissue infections
- Staphylococcus aureus*, 79–80, 190, 198, 213, 226, 243–244, 253
- Staphylococcus epidermidis*, 213, 244
- Staphylococcus saprophyticus*, 259
- Stasis dermatitis, 194
- Stavudine, 174, 177
- Stings, 194. *See also* Skin and soft tissue infections
- Streptococcus agalactiae*, 146, 253
- Streptococcus pneumoniae*, 3, 5, 26, 37, 61, 226, 253, 256, 281
- Streptococcus pyogenes*. *See* Group A β -hemolytic streptococci
- Streptococcus viridans*, 243
- Streptomycin, 12
- Sulfamethoxazole (SMX), 83, 112, 169
- Sulfisoxazole, 269
- Superficial thrombophlebitis, 194
- Sweets syndrome, 194
- Synovial fluid analysis, 228–229
- Syphilis
 background of, 113–114
 latent, 116–118
 management of sex partners, 114–115
 primary and secondary, 115–116
 serologic testing of, 114
 tertiary, 118
 treatment of, 114
- T**
- TB. *See* Tuberculosis
- TEE. *See* Transesophageal echocardiography
- Tenofovir, 174
- Terconazole, 143
- Tertiary syphilis, treatment of, 118
- Tetanus vaccination, 199–200
- Tetracycline, 12, 115, 117, 233
- Thyroiditis, in pharyngitis, 19
- Tinidazole, 126, 141–142
- Tioconazole, 143
- TMP-SMX. *See*
 Trimethoprim-sulfamethoxazole
- T. pallidum* particle agglutination, 114
- TP-PA. *See* *T. pallidum* particle agglutination
- Transesophageal echocardiography, 246
- Transthoracic echocardiography, 246
- Transurethral resection of the prostate, 267
- Trauma/exertional irritation, 19
- Treponema pallidum*, 107, 120
- Trichloroacetic acid (TCA), 154
- Trichomonas vaginalis*, 124, 126, 136, 140–142
- Trichomoniasis, 140–142
- Trimethoprim, 83, 112
- Trimethoprim-sulfamethoxazole, 29, 61, 83, 199, 201, 233, 270
- Truvada™, 174
- TST. *See* Tuberculin skin test
- TTE. *See* Transthoracic echocardiography
- Tuberculin skin test, 48
- Tuberculosis
 diagnosis of, 50–52
 epidemiology of, 45
 LTBI treatment, 52–55
 pathophysiology of, 46
 risk of, 46–47
 screening and diagnosis for, 47–48
 testing for, 48–50

- TURP. *See* Transurethral resection of the prostate
- Tympanostomy tubes, 30
- U**
- Ultrasonography (USN), 92
- Uncomplicated UTIs, treatment of, 270–271
- Upper respiratory tract infections
- acute bronchitis, 40–42
 - acute otitis media
 - bacterial pathogens and vaccinations for, 26
 - diagnosis of, 26–27
 - epidemiology and risk factors, 25
 - treatment of, 27–30
 - acute sinusitis
 - clinical presentation and epidemiology of, 58
 - diagnosis of, 59–61
 - nasal steroids, 62
 - pathophysiology, 57–58
 - treatment of, 61–62
 - chronic obstructive pulmonary disease, 6
 - causes of, 33–34
 - diagnosis of, 34–35
 - discharge of patients, 40
 - pathogenesis of, 33
 - therapies for, 36–40
 - community-acquired pneumonia
 - chest radiography and pathogens in, 4
 - diagnostic testing methods for, 4–6
 - discharge of patient, 11
 - epidemiology of, 3
 - performance assessment of, 13
 - specific antibacterial agents, 9–11
 - treatment of, 7–9
 - pharyngitis
 - causes and diagnosis for, 18–19
 - clinical manifestation of, 16–17
 - complications in, 20–22
 - epidemiology, 15
 - laboratory diagnostics for, 17–18
 - management of, 22–23
 - pathophysiology of, 16
 - therapy for, 19–20
 - tuberculosis
 - diagnosis of, 50–52
 - epidemiology of, 45
 - LTBI treatment, 52–55
 - pathophysiology of, 46
 - risk of, 46–47
 - screening and diagnosis for, 47–48
 - testing for, 48–50
- Ureaplasma urealyticum*, 124, 126, 146
- Urethritis
 - etiology of, 124
 - laboratory tests of, 124–125
 - management of patient in, 125
 - treatment of, 125–126
- Urinary tract infections
 - causes and symptoms of, 259–261
 - diagnosis of, 264–267
 - epidemiology of, 259
 - history of, 261–263
 - physical examination of, 263–264
 - treatments for, 267–273
- US Preventive Services Task Force (USPSTF), 131
- UTIs. *See* Urinary tract infections
- V**
- Vaginal discharge, 136
 - bacterial vaginosis
 - diagnosis of, 137
 - HIV infection and, 140
 - pregnancy and, 139–140
 - treatment of, 137–139
 - trichomoniasis, 140
 - pregnancy and, 141–142
 - treatment of, 141
 - vulvovaginal candidiasis, 136
 - complicated VVC, 144
 - HIV infection and, 145
 - nonalbicans VVC, 145
 - severe VVC, 145
 - uncomplicated VVC, 142–144- Valacyclovir, 109–110
- Vancomycin, 196, 256
- Vancomycin-resistant enterococcus, 245
- VAP. *See* Ventilator-associated pneumonia
- VAQTA, 88
- Varicella zoster virus, 87
 - vaccination for, 279–280
- VCUG. *See* Voiding cystourethrogram
- VDRL. *See* Venereal Disease Research Laboratory
- Venereal Disease Research Laboratory, 114, 171
- Ventilator-associated pneumonia, 9
- Vibrio cholera*, 80
- Viral meningitis, 255
- Viral pathogens and pharyngitis, 18–19
- Viral pneumonia, 6
- Voiding cystourethrogram, 267
- VRE. *See* Vancomycin-resistant enterococcus

Vulvovaginal candidiasis (VVC), 136, 142–145
VZV. *See* Varicella zoster virus

W

Wait and see prescriptions (WASPs), 28
Wells syndrome, 194
White blood cell count (WBC) count, 195

Y

Yersinia pestis, 12

Z

Zalcitabine, 174
Zanamivir, 6
Zidovudine, 174, 177, 180–181